BLCO

Bausch + Lomb Corporation
$17.15
-0.19 (-1.10%)
Mkt Cap 6.13B
Volume 358,671
52W Range 13.765-18.92
Sector Healthcare
Beta 0.56
EPS (TTM) -0.48 USD
P/E Ratio -16.75
Revenue (TTM) 5.32B USD
Rev Growth (5Y) +8.4%
EPS Growth (5Y) N/A
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
30.0 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018
Revenue 5.10B 4.79B 4.15B 3.77B 3.77B 3.41B 3.78B 3.67B
Net Income (360.00M) (317.00M) (260.00M) 6.00M 182.00M (18.00M) 298.00M 710.00M
EPS -1.02 -0.90 -0.74 0.04 0.52 -0.05 0.85 2.03
Free Cash Flow (66.00M) (59.00M) (198.00M) 170.00M 680.00M 263.00M 619.00M 662.00M
FCF / Share -0.19 -0.17 -0.56 0.49 1.94 0.75 1.77 1.89
Operating CF 283.00M 232.00M (17.00M) 345.00M 873.00M 522.00M 799.00M 763.00M
Total Assets 14.02B 13.47B 13.44B 11.14B 10.82B 11.27B 11.47B N/A
Total Debt 5.37B 4.94B 4.68B 2.55B 140.00M 101.00M 93.00M N/A
Cash & Equiv 383.00M 305.00M 334.00M 380.00M 174.00M 238.00M 192.00M N/A
Book Value 6.45B 6.47B 6.85B 7.03B 9.33B 9.92B 9.96B N/A
Return on Equity -0.06 -0.05 -0.04 0.00 0.02 -0.00 0.03 N/A
BLCO News
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
Oct 06, 2026 12:30 PM · businesswire.com
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
Oct 05, 2026 03:30 AM · businesswire.com
Head to Head Survey: Bausch + Lomb (NYSE:BLCO) vs. Terumo (OTCMKTS:TRUMY)
Oct 04, 2026 12:14 PM · defenseworld.net
Financial Survey: Merit Medical Systems (NASDAQ:MMSI) vs. Bausch + Lomb (NYSE:BLCO)
Sep 23, 2026 10:29 PM · defenseworld.net
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
Sep 14, 2026 08:16 AM · zacks.com
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
Sep 11, 2026 02:11 AM · businesswire.com
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
Sep 02, 2026 03:00 AM · businesswire.com
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
Sep 01, 2026 02:58 AM · businesswire.com
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
Aug 25, 2026 08:56 AM · zacks.com
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
Aug 25, 2026 03:39 AM · seekingalpha.com